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Glioblastoma (GBM) is the most common primary brain tumor occurring in America. Despite recent advances in therapeutics,
the prognosis for patients with newly diagnosed GBM remains dismal. As these tumors characteristically show evidence of
angiogenesis (neovascularization) there has been great interest in developing anti-angiogenic therapeutic strategies for the
treatment of patients with this disease and some anti-angiogenic agents have now been used for the treatment of patients with
malignant glioma tumors. Although the results of these clinical trials are promising in that they indicate an initial therapeutic
response, the anti-angiogenic therapies tested to date have not changed the overall survival of patients with malignant glioma
tumors. This is due, in large part, to the development of resistance to these therapies. Ongoing research into key features of the
neovasculature in malignant glioma tumors, as well as the general angiogenesis process, is suggesting additional molecules that
may be targeted and an improved response when both the neovasculature and the tumor cells are targeted. Prevention of the
development of resistance may require the development of anti-angiogenic strategies that induce apoptosis or cell death of the
neovasculature, as well as an improved understanding of the potential roles of circulating endothelial progenitor cells and vascular
co-option by tumor cells, in the development of resistance.
1.Introduction
Malignant gliomas include WHO grade IV gliomas, also
known as glioblastomas (GBM), and WHO grade III
gliomas referred to as anaplastic gliomas (AG) (anaplastic
astrocytoma, anaplastic oligodendroglioma, and anaplastic
oligoastrocytoma). GBM is the most common primary brain
tumor occurring in the United States of America; approxi-
mately 10,000 new cases are diagnosed each year [1, 2]. In
this review, we will focus on the status of antiangiogenic
therapy for GBM, as these tumors characteristically show
evidence of angiogenesis (neovascularization) on histologic
examination. Despite recent advances in therapeutics, the
prognosis for patients with newly diagnosed GBM remains
dismal; the median survival is 15 months when treated
with the current standard of therapy, which is a combina-
tion of maximal surgical resection followed by concurrent
chemoradiation and six months of adjuvant temozolomide
[3]. Most patients with GBM develop tumor recurrence
after the above therapy, and many centers are now treating
these patients with bevacizumab (a monoclonal antibody to
vascular endothelial growth factor (VEGF) that was recently
approved by the FDA). Although clearly of beneﬁt to some
patients, the majority die within 6-9 months after initiation
of anti-VEGF therapy [4–6]. Other antiangiogenic agents
also have been examined in phase I or II clinical trials for
patients with GBM, and promising results have emerged;
however, a statistically signiﬁcant increase in overall survival
has not been reported to date. It is now becoming apparent
thattumorsalsocanacttoenhancetheirvasculaturethrough
other mechanisms such as “co-option” of the existing
vasculature. The contribution of these processes to tumor
vascularization and their potential eﬀects on anti-angiogenic
therapies is an emerging ﬁeld of great interest.2 Journal of Oncology
2. The Biology of Brain Tumor Vascularization
GBMs are among the most vascular tumors known and
hence the tumor-associated vasculature is an attractive ther-
apeutic target [7]. It is now well established that tumors can
promote the formation of new vessels through the process
of angiogenesis. It is thought that when a tumor reaches a
certain size, the requirements for oxygen and nutrients lead
to the growth of new blood vessels [8, 9]. The neovasculature
that is formed in GBM never completely matures; however,
this leads to an atypical vasculature that is constantly
undergoing remodeling. There also is evidence to suggest
that prior to the triggering of the process of formation of
new vessels, tumor cells can obtain the necessary nutrients
and oxygen by “co-opting” existing blood vessels [10]. This
process appears to occur in very small tumors and appears
to be dependent on the microenvironment in the speciﬁc
organ and perhaps on the tumor type. In transplanted C6 rat
gliomasintheratbrainco-optionofexistingbloodvesselsby
tumor cells occurred initially when the tumors were several
mmindiameter,andthiswasfollowedbyvascularregression
and ultimately by the development of a neovasculature [10].
Moreover, the process of vasculogenic mimicry [11], in
which tumor cells function as blood vessel lining cells, may
contribute to the blood supply in malignant tumors. Most
of the research concerning tumor vasculature has focused on
the mechanisms that promote the formation of new blood
vessels through the process of angiogenesis and it is these
mechanisms that have been targeted in the development
of antiangiogenic therapies. Currently, relatively little is
known concerning the mechanisms underlying co-option
of blood vessels and vasculogenic mimicry, the eﬀects of
anti-angiogenic therapies on these processes, or the role of
these processes in the activity of, or resistance to, the anti-
angiogenic therapies that have been developed.
2.1. Angiogenic Growth Factors: Their Receptors and Function.
The signaling of VEGF, a proangiogenic growth factor, is
important for GBM angiogenesis and involves paracrine
interactions between the glioma cells, and the inﬂammatory
cellsthatsecreteVEGF,andthetumor-associatedendothelial
cells (EC) that express receptors for VEGF (VEGFR) [9].
The VEGF gene family is composed of ﬁve members: VEGF-
A, VEGF-B, VEGF-C, VEGF-D, and the placental-derived
growth factor (PlGF) [10–12]. Of these, family members
VEGF-A, VEGF-B, and PlGF are involved in vascular
angiogenesis, whereas VEGF-C and -D regulate lymphatic
angiogenesis [9]. VEGF-A was originally discovered as a
factor that induces vascular permeability, and has since been
shown to be an important EC mitogen [13, 14]. It belongs
to the platelet-derived growth factor (PDGF) superfamily
and is located on chromosome 6 [15]. Once secreted by the
tumor cells, stromal cells or ECs, VEGF can be tethered in
the extracellular matrix (ECM) due to an association with
proteoglycans or glycosaminoglycans [16, 17].
T h em a i nr e c e p t o r sf o rV E G F - Aa r eV E G F R 1a n d
VEGFR2 [15]. These receptors are upregulated on the ECs in
G B Ma sc o m p a r e dt ot h eE C so fn o r m a lb r a i n[ 18]. VEGFR-
2 is a major mediator of the mitogenic and angiogenic eﬀects
of VEGF through its activation of the phosphatidyl inositol
3-kinase (PI3K)/protein kinase B (AKT) and RAF-MAPK
kinase-(MEK-) extracellular signal-regulated (ERK) MAP
kinase pathways [15].
Basic ﬁbroblast growth factor (bFGF) is another proan-
giogenic growth factor that is upregulated in GBM, in which
it is expressed focally by tumor cells and also is expressed
by the vasculature [19, 20]. The receptors for bFGF include
FGFR1, FGFR2, and FGFR4. FGFR1 is upregulated in GBM
and is expressed by both the tumor cells and the tumor ECs.
FGFR4 is expressed only by the tumor cells, and FGFR2 is
not expressed in the tumors but it is expressed in the normal
brain [21, 22]. As is the case for VEGF, once secreted by
the tumor cells, stromal cells or ECs, bFGF can be tethered
in the ECM due to an association with proteoglycans or
glycosaminoglycans [16, 17]. Binding of bFGF to its receptor
resultsinactivationoftheproteinkinaseCα(PKCα)path way
[23, 24] and the ERK pathway [23, 25].
In addition to VEGF and bFGF, several other proangio-
genic molecules have been implicated in the initiation or
ampliﬁcation of angiogenesis in GBM including stem cell
factor (SCF) and interleukin-8 (IL-8), hepatocyte growth
factor and urokinase [26–30]. SCF mediates its signals
through activation of the c-KIT receptor and may be of
particular interest in GBM as its overexpression is associated
with a shorter survival in patients with malignant glioma
[31].IL-8isachemokinethatissynthesizedbymacrophages,
ECs (where it is stored in the Weibel-Palade bodies), and
other cell types (such as epithelial cells) [32, 33]. IL-8 is
releasedfrommacrophagesasaresultofahostinﬂammatory
response and activates ECs through the chemokine-1 and 2
receptors (CXCR1 and CXCR2) [34].
Finally, in normal blood vessels, angiopoietin-1 (Ang-
1) is expressed by pericytes, binds the Tie2 tyrosine kinase
receptor expressed on the associated EC and signals for
survival and stabilization of the blood vessel [35, 36]. In
GBM there is increased expression of both Ang-1 and its
antagonist angiopoietin-2 (Ang-2); Ang-2 is expressed by
the ECs, whereas Ang-1 is expressed by the tumor cells
and is not expressed by the tumor blood vessels [37]. This
has led investigators to speculate that Ang-2 may have a
proangiogenic function in the neovasculature of tumors. Of
note, Ang-2 expression has been implicated in the co-option
p r o c e s sa sd e s c r i b e db e l o w[ 10].
2.2. Proteolytic Degradation of the Basement Membrane,
Endothelial Cell Sprouting, and Tube Formation. Proteolytic
degradation of the EC basement membrane by matrix met-
alloproteinases (MMPs) exposes the ECs to ECM proteins
that can regulate angiogenesis and promote EC movement
or sprouting [11, 28, 31]. These cell-ECM interactions occur
through speciﬁc receptors and binding partners expressed
on the EC surface, such as integrin cell adhesion receptors
that recognize speciﬁc ECM molecules [9, 28, 34, 38, 39]. In
addition, integrin receptors cooperate, collaborate, or cross-
talk with growth factor receptors in a speciﬁc manner to
enhance the signaling of both the integrin and the growth
factor receptor. For example, in the chick chorioallantoicJournal of Oncology 3
membrane model of angiogenesis, integrins αvβ5a n dαvβ3,
which are expressed on the EC, bind ligands in the chorioal-
lantoic membrane and promote EC survival, proliferation,
and sprouting (migration) by cooperating with VEGFR2
and FGFR, respectively [39]. At the same time, activation of
the platelet-derived growth factor (PDGF) receptor signaling
pathway recruits pericytes to the new EC tube, where they
deposit ECM proteins that aid in the formation of a new EC
basement membrane, inducing the expression of ﬁbronectin
and nidogen-1 by the ECs [40–43]. Pericyte recruitment
to the EC tube also promotes the upregulation of certain
integrin receptors (α6β1, α3β1, α1β1, and α5β1) on the
ECs that mediate the interaction of the EC with ﬁbronectin,
nidogen-1, and laminin in the new basement membrane
[42, 43].
Pericytes are necessary for stabilization of the new EC
tube. The ﬁnding that EC tubes lacking pericyte coverage
become dilated [42] suggests that pericyte coverage of
the EC tube is necessary for maintaining the appropriate
vessel diameter. This concept is consistent with the dilated
and tortuous blood vessels that are observed on histologic
examination of many GBM tumors and suggests that this
may be associated with the reduced pericyte coverage of
blood vessels observed in these tumors [36, 44].
Endothelial progenitor cells (EPCs) from the bone
marrow may also contribute to the neovasculature. EPCs
are mobilized from the bone marrow by the cytokine
stromal-derived factor-1α (SDF-1α)[ 45] that is expressed
by angiogenic vessels in GBM, SDF1α binds to the G
protein-coupled chemokine 4 receptor (CXCR4) expressed
on circulating EPCs and also on tumor vessels [46]. A role
for the SDF1α/CXCR4 signaling pathway in the development
or maintenance of the GBM neovasculature is suggested
by a report that demonstrated that the administration of a
CXCR4 antagonist to an orthotopic xenograft mouse model
of GBM inhibited tumor growth [47].
2.3.AbnormalitiesintheNeovasculatureofGBMandHypoxia.
The failure of the GBM neovasculature to mature completely
resultsinanatypicalneovasculaturethatdemonstratesexces-
sive leakiness and lacks a normal blood brain barrier (BBB).
Electron microscopic examination of the neovasculature in
GBM has revealed that the tight junctions and adherens
junctions (important contributors to the BBB) are abnormal
and that the actin ﬁlaments associated with the junctions are
disorganized [48]. These changes likely decrease the osmotic
gradient between the vasculature and interstitium, elevating
the interstitial ﬂuid pressure in the tumor [49]. This has
certain important clinical implications. First, the elevated
interstitial ﬂuid pressure can compromise drug delivery to
the GBM. Second, the abnormalities in the neovasculature
may enhance tumor cell access to the vasculature and aid in
tumor cell migration and invasion along the EC basement
membrane to previously uninvolved brain tissue.
In addition, the neovasculature in GBM demonstrates
prominent thrombosis, promoting local hypoxia within the
tumor. This local hypoxia is exacerbated by the rapid growth
of these tumors, which frequently results in an extensive
necroticcorethatfurtheraccentuatesthehypoxicmicroenvi-
ronment. Hypoxia can promote tumor angiogenesis through
activation of the transcription factor hypoxia-inducible
factor -1α (HIF-1α) which, in turn, enhances production
of proangiogenic growth factors. Normally, the von Hippel-
Lindau (VHL) molecule inhibits the function of HIF-1α but
hypoxia destabilizes VHL causing it to dissociate from HIF-
1α. This results in HIF-1α binding to the hypoxia response
element (HRE) in the promoter of several proangiogenic
factors (i.e., VEGF and SDF-1α) thereby initiating their
transcription [45, 50]. A second HIF family member, HIF-
2α, is also activated by hypoxia and likely plays a role
in promoting tumor angiogenesis in GBM [51]. Li and
colleagues [51] have recently demonstrated that HIF-2α is
preferentially expressed in glioma stem cells, in comparison
tononstemtumorcellsandnormalneuralprogenitors.Their
work showed that HIF2α,n o tH I F 1 α, is selectively activated
in glioma stem cells by hypoxia, inducing the expression of
VEGF. In tumor specimens, HIF2α colocalized with markers
of cancer stem cells. Furthermore, targeting HIF in glioma
stem cells inhibited self-renewal, proliferation, and survival
in vitro, and attenuated the tumor initiation potential of
glioma stem cells in mouse xenografts. Therefore, HIF2α
likely represents a promising new therapeutic target in
patients with GBM [51].
2.4. Role of Cancer Stem Cells in Tumor Angiogenesis. In
recent years, a minor population of cells has been identiﬁed
in GBM and other malignant tumors that has characteristics
of tumor-initiating cells. These cells have been referred to
as cancer stem cells (CSCs) and in the case of GBM are
referred to as glioma stem cells [52–54]. There is still some
debate regarding the appropriate deﬁnition of CSCs, but
an emerging consensus holds that these cells are capable of
self-renewal, sustained proliferation, and initiating tumor
formation when injected in very low numbers into an
immunocompromised mouse host [55]. Of particular rele-
vance to this review, a small but growing number of papers
have suggested that CSCs promote angiogenesis in tumors.
For example, Bao and colleagues (2006) demonstrated that
conditioned media from glioma stem cells signiﬁcantly
promoted EC migration, proliferation, and tube formation
as compared to conditioned media from nonstem glioma
cells [56]. Consistent with this observation, Calabrese and
colleagues (2007) showed that ECs interact closely with
brain tumor stem cells in the perivascular location (this
has been termed a vascular niche) and secrete factors that
maintainthesecellsinastemcell-likestate[57].Investigators
have speculated that this vascular niche is an important
target for therapeutic intervention, as disruption of the niche
microenvironment can ablate the growth of CSCs and arrest
tumor growth [57, 58]. It should therefore be borne in mind
that this is a potential mechanism by which anti-angiogenic
drugs could inhibit brain tumor growth [57]. Most recently,
Folkins and colleagues (2009) compared the angiogenesis in
tumor xenografts from C6 glioma cells containing either a
low or a high fraction of CSCs, and found that CSC-high
xenograft tumors demonstrated an increased microvessel4 Journal of Oncology
density and blood perfusion, as well as inducing greater
mobilization and recruitment of bone marrow-derived EPCs
to the tumors [59]. Also, the CSC-high C6 cultures and
xenograft tumors expressed higher levels of VEGF and SDF1,
and blocking of these proangiogenic factors resulted in a
reduction in the growth of the tumors compared to that
observed with CSC low C6 cells [59]. These data suggest
thatCSCsdocontributetotumorangiogenesisbypromoting
both local EC activity and systemic angiogenic processes that
involve the recruitment of bone marrow-derived EPC in a
VEGF-and SDF1-dependent manner [59].
2.5. Role of Bone Marrow-Derived Progenitor Cells in Tumor
Angiogenesis. There is evidence that the adult bone marrow
playsasigniﬁcantroleinendothelialandlymphaticneovessel
formationthatsupportstumorgrowthandinvasion[60,61].
As the brain lacks a lymphatic system, lymphatic neovessel
formation is not relevant for GBM. The nonhematopoietic
(CD45−)bonemarrow-derivedpopulationofcellsthatlikely
contribute to tumor angiogenesis, bone marrow-derived
EPCs, may directly contribute to the EC layer by merging
with the wall of a growing blood vessel and diﬀerentiating
into ECs, thereby providing an alternative source of ECs
[62]. The circulating EPCs originally reported by Asahara
et al. (1997) (deﬁned as CD34+/ VEGFR2+) were shown
to be capable of diﬀerentiating into an EC phenotype
that expressed EC markers in vitro, and to be capable
of incorporating into neovessels at sites of ischemia [62].
Shaked and colleagues (2006) showed that administration
of a vascular disrupting agent, such as combretastatin, or
chemotherapeutic drugs, such as Paclitaxel or 5-ﬂuorouracil,
to a mouse model of cancer resulted in the recruitment of
bone marrow-derived EPCs to the tumor as well as severe
tumor necrosis [63]. Other studies have suggested that circu-
lating EPCs may contribute to tumor neovascularization in
mouse models of cancer [64].
It should be noted that the contribution of circulating
EPCs to neoangiogenesis has been questioned and the
markers that identify bone marrow-derived EPCs have been
debated vigorously [65, 66]. The reported level of incor-
poration of circulating EPCs into new blood vessels varies
considerably and ranges in diﬀerent studies from 5% to 50%
[53, 63, 65, 67]. In addition, technical challenges exist in
identifying vessel-incorporated bone marrow-derived EPCs.
Most recently, Rafat and colleagues (2009) suggested that in
12 patients with GBM higher numbers of circulating EPCs
appeared to correlate with a signiﬁcantly higher tumor vessel
density, as compared to patients with lower numbers of
circulating EPCs [68]; however, this observation needs to be
validated in a larger study.
Bone marrow-derived hematopoietic cells have also
been reported to contribute to tumor angiogenesis and
invasion. Unlike the circulating EPCs discussed above,
these cells are CD45+, and they include myeloid pro-
genitor cells identiﬁed as GR1+CD11b
+ in the mouse
(in the human CD3+, CD14+, CD19+, CD57+ and
HLA-DR negative) [69], CD11b
+F4/80+ tumor-associated
macrophages (TAMs) [70], Tie2-expressing monocytes
[71], CXCR4+VEGFR1+ hemangiocytes [72], bone marrow-
derived circulating cells that comprise a heterogeneous
population of myeloid cells identiﬁed as CD45+CD11b
+ in
the mouse and human [73], platelet-derived growth factor
receptor (PDGFR)+ pericyte progenitors [74], and vascular
endothelial-(VE-) cadherin+ CD45+ leukocytes [75]. Sup-
porting their potential importance in the response of the
tumor to therapy, Shojaei and Ferrara reported that the
recruitment of bone marrow-derived GR1+ myeloid cells
resulted in a tumor that was refractory to treatment with
inhibitors of VEGF [76]. In general, the above CD45+
bone marrow-derived cells are not thought to incorporate
into the EC layer of the new vasculature; rather, some of
the above cells are thought to incorporate into the tumor
neovasculature as perivascular cells where they function to
promote angiogenesis through paracrine mechanisms, such
as local secretion of VEGF [73].
2.6. Co-Option of Existing Blood Vessels Occurs in Very Small
Tumors. As discussed above, there is evidence to suggest
that in small tumors, in which the neovasculature has not
developed,thetumorcellsobtainthenecessarynutrientsand
oxygenneededforgrowthbyco-optingexistingbloodvessels
[10]. Of note, in transplanted C6 rat gliomas in the rat brain
co-option of existing blood vessels by tumor cells occurred
initially when the tumors were several mm in diameter, and
this was followed by vascular regression and ultimately by
the development of a neovasculature [10]. The same study
also showed co-option of existing blood vessels with the
propagation of rat mammary cancer cells in the rat brain
and with the metastasis of Lewis lung cancer cells to the
lung after intravenous injection. In each of these models,
Ang-2 expression was upregulated at the co-opted blood
vessels, suggesting a role for Ang-2 signaling in the co-option
process [10]. Vessel co-option has been observed in several
other tumors, including melanoma, ovarian carcinoma, and
Kaposi sarcoma (reviewed in [11]).
Another mechanism contributing to the blood supply
in malignant tumors is vasculogenic mimicry [11]. In
vasculogenic mimicry, tumor cells function as blood vessel
lining cells and this has been described in several types of
malignant tumors, including melanoma [11].
3. ClinicalUse of AntiangiogenicAgents
3.1.VEGFInhibitors. Bevacizumabisamonoclonalantibody
directedtowardVEGFthathasbecometheprototypeofanti-
angiogenic agents in clinical use for treatment of GBM (see
Table 1). In a phase II clinical trial, 68 patients with recurrent
malignant glioma (33AG and 35GBM) were treated with
bevacizumab and irinotecan in two cohorts (see Table 2).
The combination therapy produced an impressive initial
radiographic response rate of 57% for GBM and 61% for
AG [5, 77]. This compared favorably with the benchmark
response rate for temozolomide therapy at the ﬁrst tumor
recurrence,5%forpatientswithrecurrentGBMand35%for
patients with recurrent AG [78–80]. With the combination
of bevacizumab and irinotecan the progression-free survivalJournal of Oncology 5
Table 1: Examples of antiangiogenic agents in clinical trial for patients with high grade glioma.
Drug Type Targets
ABT-510 Thrombospondin-1 mimetic peptide CD36 receptor
AMG 102 Monoclonal antibody HGF/SF
Aﬂibercept Soluble decoy receptor VEGF-A,B, PlGF
Bevacizumab Monoclonal antibody VEGF-A
Brivanib Tyrosine kinase inhibitor FGFR, VEGFR2
Cediranib Tyrosine kinase inhibitor VEGFR1–3, PDGFRβ,c - K i t
Cilengitide RGD synthetic peptide Integrins αvβ3, αvβ5
CT-322 Fibronectin (adnectin)-based inhibitor VEGFR1–3
Dasatinib Tyrosine kinase inhibitor PDGFRβ, Src, BCR-ABL, c-Kit, EphA2
Imatinib Tyrosine kinase inhibitor PDGFRβ, BCR-ABL, c-Kit
Lenalidomide Immunomodulatory and anti-inﬂammatory FGF pathway
Pazopanib (GW786034) Tyrosine kinase inhibitor VEGFR1–3, PDGFRβ,c - K i t
Sorafenib Tyrosine kinase inhibitor VEGFR2,3, BRAF, PDGFRβ,c - K i t ,R a s ,p 3 8 α
Sunitinib Tyrosine kinase inhibitor VEGFR2, PDGFRβ, Flt3, c-Kit
Tandutinib (MLN518) Tyrosine kinase inhibitor PDGFRβ, Flt3, c-Kit
Vandetanib (ZD6474) Tyrosine kinase inhibitor VEGFR2, EGFR, RET
Vatalanib (PTK787) Tyrosine kinase inhibitor VEGFR1–3, PDGFRβ,c - K i t
XL-184 Tyrosine kinase inhibitor VEGFR2, Met, RET, c-Kit, Flt3, Tie-2
A more complete listing of anti-angiogenic agents in clinical trials for patients with high grade gliomas can be found at the National Institutes of Health
website http://www.clinicaltrials.gov/ when searching for “glioma, brain cancer, glioblastoma, and angiogenesis”.
at six months (PFS-6) was 43% for recurrent GBM patients
and 59% for AG patients, and this was an improvement over
the accepted PFS-6 standard of 15% for GBM patients and
31% for AG patients treated with temozolomide [79, 80].
Therapy with bevacizumab and irinotecan also resulted in
neurological improvement and a reduction or discontinua-
tionintheuseofcorticosteroidtreatmentin31%ofpatients.
The regimen was well tolerated; only one CNS hemorrhage
was reported in 68 patients treated, eight patients were
taken oﬀ of the study for thrombotic complications (four
patients with pulmonary embolism (PE), two with deep
vein thrombosis, one with thrombotic thrombocytopenic
purpura, and one with thrombotic stroke), and two patients
died (one with PE and one with a thrombotic stroke).
Other side eﬀects reported included, proteinuria, fatigue,
and gastro-intestinal toxicity; these have been described
with bevacizumab therapy for other types of cancer. Other
prospective and retrospective studies have demonstrated
initial radiographic response rates of between 35% and
50% with the combination of bevacizumab and cytotoxic
chemotherapy [4, 81–83].
Asirinotecanhaslimitedactivityasasingleagent,aphase
II randomized clinical trial was performed to evaluate the
beneﬁt of the addition of irinotecan to bevacizumab. In this
clinical trial 167 patients with recurrent GBM received either
bevacizumab alone or bevacizumab in combination with
irinotecan; there was no statistically signiﬁcant diﬀerence in
the median overall survival (OS) for bevacizumab therapy
alone (9.2 months) when compared to the combination
bevacizumab and irinotecan therapy (8.7 months) [6].
A recent study evaluated the approach of bevacizumab
monotherapy in patients with recurrent GBM followed
by irinotecan combined with bevacizumab [84]. In this
study, 17/48 patients (35%) achieved an initial radiographic
response and the PFS-6 was reported to be 29%. Addition
of irinotecan to patients who progress on bevacizumab
monotherapy failed to produce an objective radiographic
response in any of the 19 patients [84]. Bevacizumab
is presently being evaluated in the upfront setting with
temozolomide and radiation in two randomized phase III
trials sponsored by the Radiation Therapy Oncology Group
and Hoﬀmann-La Roche [85, 86].
OtherVEGF/VEGFR-targetedinhibitorsinclude,A ﬂiber -
cept,asolubleVEGFdecoyorhybridreceptorthatconsistsof
portionsofVEGFR-1and-2fusedtoanimmunoglobulinG1
Fc region [87–89]a n dCediranib (AZD2171), a pan-VEGFR
tyrosine kinase inhibitor with activity against PDGFR and c-
KIT [90] (see Table 1).
4.MultikinaseReceptorsInhibitors(MTKI)
A number of MTKIs have been studied in GBM patients
(see Tables 1 and 2) including,I m a t i n i b[95–99], Sorafenib
[100–102], Sunitinib [103], Vandetanib (ZD6474) [104–
107], Vatalanib (PTK787) [91, 108–114], and XL184 [92,
115–117].
5. Other Anti-AngiogenicAgents
Other anti-angiogenic agents evaluated in GBM (see Tables
1 and 2) include, Thalidomide [93, 118–123], Lenalidomide
[124, 125], Tamoxifen [126–129], Enzastaurin (LY317615)
[130, 131], and the integrin inhibitor Cilengitide [94, 132,
133].6 Journal of Oncology
Table 2: Selected clinical trials in patients with recurrent high grade glioma
Agent Phase Diagnosis Number of patients
and Histology Response Rate PFS-6
Bev + Ir [5, 77] II Recurrent MG 68 (33AG, 35GBM) 43% GBM, 59% AG
B e vv e r s u sB e v+I r[ 6] II Recurrent GBM 85GBM (Bev) Vs
82GBM (Bev +Ir)
RRR = 28% (Bev), RRR = 37%
(Bev +Ir)
42% (Bev) versus
50% (Bev + Ir)
Aﬂibercept [89] II Recurrent MG 48 (16AG, 32GBM) 50% AG30% GBM
Cediranib [90] II Recurrent GBM 16GBM 56%
Vatalanib [91] I/II Recurrent GBM 55GBM PR = 4%, SD = 56%
XL184 [92] II Recurrent GBM 26GBM PR = 38%
Thalidomide [93] II Recurrent MG 39 (14AG, 25GBM) PR = 6%, MR = 6%, SD = 33%
Cilengitide [94] II Recurrent GBM 81GBM 16%
Abbreviations: Bev: bevacizumab, Ir: Irinotecan, PFS-6: progression free survival at 6 months, MG: malignant glioma, GBM: glioblastoma, AG: anaplastic
glioma (includes anaplastic astrocytoma, anaplastic oligodendrogioma and anaplastic oligoastrocytoma), RR: response rate, RRR: radiological response rate,
PR: partial response, SD: stable disease, MR: minor response, TMZ: temozolomide, and XRT: radiation.
6. Challenges inEvaluatingthe Response to
Anti-AngiogenicTherapy with Imaging
The Macdonald Criteria have been used since 1990 to deﬁne
response or progression in clinical trials of malignant glioma
[134]. The Macdonald Criteria, based on WHO Criteria,
utilizes measurement of the largest cross-sectional area of
tumor on contrast-enhanced CT or MRI scan. Malignant
gliomas can be irregular in shape, include large necrotic
cavities,orbepartiallyorcompletelynonenhancing,creating
diﬃculty in accurately measuring the largest cross-sectional
area on contrast-enhanced CT or MRI scan. In addition,
the interpreter needs to take into account concurrent cor-
ticosteroid use and changes in neurological function. Thus,
response evaluation based on ﬁnding a diﬀerence in the
largest cross-sectional area of tumor on contrast-enhanced
CT or MRI is even more diﬃcult with anti-angiogenic
therapy.
Clinical trials with drugs that modify signal transduction
throughtheVEGFsignalingpathway(e.g.,bevacizumab,and
cediranib) can produce a rapid decrease in enhancement
after initiation of therapy [5, 135], resulting in an apparent
high response rate. Some of the changes observed on
contrast-enhanced CT or MRI scan result from a rapid
normalization of abnormally permeable blood vessels and
are not due to an antitumor eﬀect. Anti-angiogenic therapy
likely decreases vascular permeability and restores at least
in part the integrity of the BBB, this leads to less contrast
leakage from the vasculature. There is evidence that VEGF
pathway-targetedanti-angiogenicdrugslikelyaltertheimage
characteristics of enhancing tumor more eﬀectively than
of nonenhancing tumor. Hence the extent of reduction
in contrast enhancement may not reﬂect true antitumor
activity of the anti-angiogenic agent. Not infrequently, the
radiographic image observed after anti-angiogenic therapy
suggests a radiographic response that is more impressive
than the clinical beneﬁt derived from the therapy. The term
“pseudoresponse” has been used to deﬁne the situation
wherein the contrast-enhanced MRI suggests an antitumor
eﬀect that does not correlate with a true clinical beneﬁt
[136]. Therefore, treatment response based on radiographic
images is probably not an optimal end point for clinical
trials evaluating anti-angiogenic agents. The international
Response Assessment in Neuro-Oncology (RANO) Working
Group has developed new criteria for evaluating tumor
response in malignant gliomas that take into account both
enhancing and nonenhancing tumor (best visualized on
T2 and ﬂuid-attenuated inversion recovery (FLAIR) MRI
sequences) images [136]. This working group proposes that
increased T2-FLAIR signal likely reﬂects growing tumor,
such as when it appears outside of the radiation ﬁeld, it
produces mass eﬀect, or it involves the cortical ribbon, and
when it occurs in the absence of other potential explanation.
7. Resistance to Anti-AngiogenicTherapy
Althoughtheanti-angiogenictherapyofpatientswithmalig-
nant glioma has resulted in a small increase in the PFS-6,
in general these agents have failed to produce a sustained
clinical response. For example, patients with malignant
glioma treated with a VEGF inhibitor have shown tem-
porary improvements, seen as reduced edema on imaging
or tumor stabilization on imaging; however, the tumors
ultimately progress after a brief response. In patients with
tumor progression during treatment with bevacizumab, the
downhill clinical course is often rapid, and may be fueled by
discontinuing the agent. In a retrospective analysis, patients
with malignant glioma who were treated with a second line
regimen containing bevacizumab after failure of treatment
with an initial therapy combination of bevacizumab and a
cytotoxic agent had a median PFS of only 37.5 days [137].
Shaked and colleagues showed that treatment withdrawal of
a vascular disrupting agent, such as combrestatin, to a mouse
model of cancer resulted in the development of an aggressive
and angiogenic tumor [63]. Supporting the concept that
malignant tumors ultimately develop resistance to therapy
with a VEGF inhibitor, two recent studies (one of whichJournal of Oncology 7
included a xenograft mouse model of GBM) suggested that
treatment with a VEGF inhibitor alters the natural history
of the tumor and promotes a highly invasive and metastatic
phenotype [138, 139].
The anti-angiogenic therapy failures described above
are thought to be due to the development of resistance
to anti-angiogenic therapy. Resistance to anti-angiogenic
therapy has been broadly classiﬁed as either adaptive or
intrinsic [140]. Animal models of malignant glioma and
of other malignant tumors have shown that tumors adapt
to treatment with angiogenesis inhibitors by upregulating,
or acquiring, an alternate mechanism(s) to sustain tumor
growth, which has been termed “adaptive evasive resistance”.
This can occur even when the speciﬁc target of the anti-
angiogenic agent remains successfully inhibited. Adaptive
resistance along with intrinsic resistance is thought to
be the reason for the progression of malignant tumors
treated with anti-angiogenic therapy. In tumors that show
an initial response to anti-angiogenic therapy, adaptive
evasive resistance is thought to be the main mechanism
for the development of resistance, that is, blockade of
one proangiogenic growth factor can lead to upregulation
of an alternate proangiogenic growth factor [141]. For
example, in a study of GBM patients treated with the pan-
VEGFR inhibitor cediranib (AZD 2171), blood levels of the
proangiogenic factors bFGF and SDF1α were noted to be
higher in patients at the time of tumor progression or relapse
as compared to the levels observed during the phase in
which the patients showed a response to cediranib therapy
[142].
Recruitment of vascular progenitor cells from the bone
marrow may aid in the process of adaptive evasive resis-
tance. Certain anti-angiogenic therapies can cause regression
of tumor vessels resulting in hypoxia and lead to the
recruitment of various bone marrow-derived progenitor
cells. Bone marrow-derived progenitor cells (including both
vascular progenitor cells and vascular modulatory cells)
can be recruited through hypoxia-induced HIF1α activation
resultingintheexpressionofthedownstreameﬀectorSDF1α
[45, 143–146]. GBM tumors with low HIF1α levels contain
fewer bone marrow-derived cells and exhibit lower levels
of angiogenesis and tumor growth, as compared to GBM
tumors with high HIF1α levels [146]. This suggests that the
recruitment of bone marrow-derived progenitor cells may
constitute a mechanism for the development of adaptive
evasive resistance to anti-angiogenic therapy.
One reason for the initial response to bevacizumab
therapy reported for some patients with GBM may be
that the GBM neovasculature typically contains a reduced
density of pericyte coverage [36]. Pericytes are important
constituents of blood vessels in general and of tumor blood
vessels, they provide prosurvival signals to ECs. ECs are
thought to induce pericyte recruitment, thereby promoting
their own survival. Two of the best characterized prosurvival
signals for ECs are VEGF and the signals derived from
pericyte association with ECs [36]. Tumor vessels lacking
adequate pericyte coverage are more vulnerable to VEGF
inhibition as they lack the pro-survival signal from pericytes
[147]. Blood vessels covered with the normal density of
pericytes probably survive therapy with a VEGF inhibitor
as the pericytes can signal for EC survival or quiescence
[148, 149].
Finally, the possibility of the development of an alter-
native mechanism, such as co-option, for tumor cells to
acquire oxygen and nutrients must be considered in terms
of resistance. Notably, in an orthotopic mouse model of
GBMtreatedwithaVEGFRselectivekinaseinhibitor orwith
a multitarget VEGFR kinase inhibitor, tumor progression
(growth) ultimately occurred that was highly invasive.
Perivascular tumor invasion similar to tumor co-option
of blood vessels was observed at autopsy. Moreover, two
other recent studies have suggested that tumor co-option
of pre-existing blood vessels can support a more invasive
tumor cell phenotype and tumor growth after VEGF- or
VEGFR2-targeted therapy [150, 151]. As Ang-2 signaling
has been implicated in mediating blood vessel co-option
in the untreated early C6 rat glioma model of malignant
glioma [10], human GBM tumors were immunostained
for Ang-1 and Ang-2 and it was reported that Ang-2
expression was upregulated at tumor co-opted blood vessels.
Whether the co-opted blood vessels that were observed post
anti-angiogenic therapy also showed upregulation of Ang-2
remains to be determined.
The second mechanism of resistance to anti-angiogenic
therapy that has been suggested is an intrinsic or inherent
resistance [140]. This concept stems from the observation
that a minority of patients do not appear to respond to anti-
angiogenic therapy. It has been suggested that this may be
due to the pre-existing activation of multiple proangiogenic
signaling pathways or a pre-existing inﬂammatory cell
inﬁltrate that provides a source of tumor VEGF resulting in
vascular protection [140].
8.The Blood-Brain Barrier(BBB) and
the Challenges of Drug Delivery
Drug concentrations within the central nervous system are
dependent on multiple factors that include, the permeability
of the agent across the BBB, the extent to which it is actively
transported out of the brain, and the volume of distribution
in the brain parenchyma [152]. The BBB is an anatomic-
physiologic barrier that is formed by multiple components,
includingtightjunctionsbetweenendothelialcells,pericytes,
and the astrocytic foot processes. This barrier selectively
allows entry of some substances, such as glucose, lipid-
soluble molecules, and oxygen, while preventing entry of
othersubstances.Itisimportanttounderstandthatalthough
the BBB may be disrupted in some areas of a GBM, a
substantial proportion of glioma cells can be located in
areas with an intact BBB. The magnitude of tumor vascular
permeability varies within these tumors, with the greatest
permeability being found in the tumor core and a relatively
intact BBB at the proliferating tumor edge. The presence
of an intact BBB in some areas of the tumor and the
presence of a partially functional BBB in other areas of the
tumor can prevent the eﬀective delivery of active therapeutic
compounds.8 Journal of Oncology
T h eB B Be x p r e s s e sh i g hl e v e l so fd r u ge ﬄux pumps such
as P-glycoprotein (P-gp), breast cancer-resistance protein
(BCRP), and other multiple drug resistance proteins (MRPs)
that actively remove chemotherapeutic drugs from the brain
[153]. Eﬄux transport systems such as by P-gp and the
MRPs at the brain capillary ECs may play a role in limiting
the passage of therapeutic agents across the BBB [154].
For example, the brain distribution of the tyrosine kinase
inhibitor imatinib is reduced by active eﬄux via the P-
glycoprotein [155]. The BCRP drug eﬄux transport pump
is expressed in a number of normal tissues, in addition to
the BBB [156]. Modulation of drug transporters represents a
new potential strategy to improve eﬃcacy of targeted agents.
Anti-angiogenic agents such bevacizumab that mainly target
the EC on the luminal side of the vessel may not depend on
the ability to cross the BBB; however, this remains a concern
for tyrosine kinase inhibitors like imatinib.
9. Biomarkers of Angiogenesis
Currently, there are no validated biomarkers to monitor the
progress or response to anti-angiogenic therapy in patients
with malignant glioma or other cancers [157]. Two promis-
ing biomarkers for assessment of angiogenesis in malignant
tumors are the number of circulating endothelial cells
(CECs)andthenumberofcirculatingendothelialprogenitor
cells (EPCs). A growing body of literature suggests that
the number of CECs and circulating EPCs is signiﬁcantly
elevated in patients with diﬀerent types of cancer [65].
Furthermore, in a small number of preclinical animal studies
successful antitumor response to anti-angiogenic therapy
was correlated with changes in the number of CECs and
circulating EPCs [158]. Rafat and colleagues have evaluated
the number of circulating EPCs in the blood of patients
with malignant glioma, and reported that they were higher
in patients with GBM as compared to healthy volunteers
[68]. Higher tumor blood vessel densities were noted in the
patients with GBM having higher numbers of circulating
EPCs as compared to those patients with lower numbers of
circulatingEPCs[68].Thissupportsthefurtherevaluationof
circulating EPCs as a novel biomarker for the assessment of
angiogenesis and for the assessment of the response to anti-
angiogenic therapy in patients with GBM.
Measurement of VEGF plasma levels may not be a gen-
erally useful biomarker of tumor angiogenesis. For example,
baseline plasma VEGF levels are not correlated with survival
outcome for patients with metastatic colorectal cancer or for
patientswithmetastaticnonsmallcelllungcancer[159,160].
As expected, the plasma level of VEGF in patients with GBM
and brain metastases is elevated as compared to normal
healthy volunteers. In patients with metastatic breast cancer
higher plasma levels of VEGF were associated with shorter
timeofprogression[161].Thus,additionalstudiesneedtobe
performedtodeterminewhetherthemeasurementofplasma
VEGF levels is useful in monitoring the response to anti-
angiogenictherapyingeneralandtoVEGFinhibitortherapy.
As previously noted, blood levels of bFGF and SDF1α were
noted to be higher in patients at the time of relapse as
comparedtolevelsobservedintheresponsephaseinpatients
with recurrent GBM treated with cediranib [142].
10. UnansweredQuestions
Despite the remarkable progress in our understanding of
the process of angiogenesis and the potential promise of
targeting these processes for the treatment of GBM, several
critical questions need to be addressed. These include
questions regarding the fundamental processes involved in
GBM vascularization and their role in the failure of therapy.
Pressing questions in this category are: (1) are the GBM
tumors in patients that have failed bevacizumab or other
anti-angiogenic therapy avascular, or are the tumors co-
opting the existing blood vessels to obtain the oxygen and
nutrients needed?, (2) is the angiopoietin signaling pathway
driving a blood vessel co-option process in human GBM that
have failed therapy with a VEGF inhibitor or other anti-
angiogenic agent?, and (3) do cancer stem cells (or glioma
stem cells) promote angiogenesis in malignant gliomas and
could we target them speciﬁcally with novel therapy?
There also is an urgent need to improve the ability
to assess the eﬀects of the anti-angiogenic therapies on
angiogenesis (rather than tumor growth). Questions in
this category include: (1) does the number of CECs and
circulating EPCs in patients with tumors correlate with
the tumor grade, and could their number be used to
monitor anti-angiogenic therapy? (Phenotyping circulating
EPCs with a comprehensive set of endothelial, progenitor,
and hematopoietic markers should be performed to address
the issue of what are the appropriate markers to be used to
identify circulating EPCs in patients [65]), (2) what is the
contributionofcirculatingEPCstoangiogenesisinuntreated
virgin tumors?, and (3) could a biomarker be identiﬁed that
would aid in identifying adaptive evasive resistance (escape
pathways) that should be targeted when a patient’s tumor
develops resistance to anti-angiogenic therapy?
11. Conclusions
Anti-angiogenic therapy appears to be a promising and
novel approach for the treatment of malignant brain tumors.
Clinical trials have shown improvement in the short-term
progression-free survival. The response of patients with
GBM to therapy with a VEGF inhibitor likely depends,
at least in part, on whether the tumor neovasculature
contains a normal density of pericytes, how capable the
tumorisinco-optingpre-existingbloodvessels,andwhether
previously co-opted blood vessels exist in the tumor. A
better understanding of the mechanisms of resistance to
anti-angiogenic therapy is needed such that we can improve
our treatment strategies for these patients. The development
and optimization of biomarkers to measure angiogenesis in
tumors, such as quantitation of the numbers of CECs and
circulating EPCs, will potentially help us identify patients
that are responding to, or failing, anti-angiogenic therapy.
Theoretically,thesemarkerscouldalsobeusedtoidentifythe
subset of patients that would beneﬁt from anti-angiogenicJournal of Oncology 9
therapyandtherebyindividualizingtherapyforpatientswith
malignant tumors, such as GBM. In addition, new anti-
angiogenic therapies that induce apoptosis of the ECs in the
neovasculature are needed, as this type of anti-angiogenic
therapy may be less likely to induce therapeutic resistance.
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